Open an account

Supernus Pharmaceuticals

SUPN · NASDAQ

$41.23+$1.39 (+3.49%)TodayMarket closed ·
Prev close $39.84

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. The company is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.

Employees
778
Headquarters
Rockville, Maryland
Listed
Dec 28, 2010
Sector
Health Care
Industry
Pharmaceuticals
Website
supernus.com

SUPN key statistics

Market cap
2.40B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
818.19K
Volume
1.24M
Open price
$39.95
High today
$41.74
Low today
$39.77
52 Week high
$59.68
52 Week low
$37.54

Supernus Pharmaceuticals (SUPN) at a glance

As of Oct 20, 2026, Supernus Pharmaceuticals (SUPN) shares are priced at $41.23, giving the company a market cap of 2.40B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $39.77 and $41.74. The current price is 3.7% above the day's low and 1.2% below its high.

Volume so far is 1.24M shares, above the average of 818.19K shares a day.

Over the past year Supernus Pharmaceuticals has ranged from $37.54 to $59.68, and now sits 17% of the way up that range.

Supernus Pharmaceuticals met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.53 per share against an estimate of $0.3631.

The average analyst price target is $63.85, 54.9% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 7 analystsAvg $63.85
Low
$55.55
Now
$41.23
High
$70.35

SUPN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 86.6% on average.

  1. Q3 FY24: reported $1.17 per share against an estimate of $0.4522
  2. Q4 FY24: reported $0.75 per share against an estimate of $0.4233
  3. Q1 FY25: reported $0.44 per share against an estimate of $0.3808
  4. Q2 FY25: reported $0.90 per share against an estimate of $0.4794
  5. Q3 FY25: reported $1.01 per share against an estimate of $0.6018
  6. Q4 FY25: reported $0.84 per share against an estimate of $0.3468
  7. Q1 FY26: reported $0.60 per share against an estimate of $0.3035
  8. Q2 FY26: reported $0.53 per share against an estimate of $0.3631

SUPN news

  • Press releasePRNewswire

    Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • Press releaseBusiness Wire

    SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

  • Press releasePRNewswire

    Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Similar companies

Companies in the same industry as Supernus Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.